Monte Rosa Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
GLUE$10.50-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of stockholders’ equity
Consolidated statements stockholders’ equity
| Common stock | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share amounts) | Shares | Amount | Additionalpaid-incapital | Accumulatedothercomprehensive loss | Accumulateddeficit | TotalStockholders’equity |
| Balance—January 1, 2024 | 50,140,233 | $5 | 547,857 | $(2,724) | $(365,888) | $179,250 |
| Restricted common stock vesting | 136,730 | — | — | — | — | — |
| Exercise of common stock options | 299,222 | — | 1,061 | — | — | 1,061 |
| Provision for pension benefit obligation | — | — | — | (802) | — | (802) |
| Stock-based compensation expense | — | — | 18,126 | — | — | 18,126 |
| Unrealized gain on available-for-sale securities | — | — | — | 170 | — | 170 |
| Issuance of shares under employee stock purchase plan | 162,279 | — | 527 | — | — | 527 |
| Issuance of common stock pursuant to the at-the market sales agreement, net of issuance costs of $89 | 130,506 | — | 884 | — | — | 884 |
| Issuance of common stock pursuant to the Underwritten Public Offering, net of issuance cost of $3,290 | 10,638,476 | 1 | 46,709 | — | — | 46,710 |
| Issuance of pre-funded warrant, net of issuance costs of $290 | — | — | 49,710 | — | — | 49,710 |
| Net loss | — | — | — | — | (72,700) | (72,700) |
| Balance—December 31, 2024 | 61,507,446 | $6 | $664,874 | $(3,356) | $(438,588) | $222,936 |
| Exercise of common stock options | 779,114 | — | 5,723 | — | — | 5,723 |
| Provision for pension benefit obligation | — | — | — | (519) | — | (519) |
| Stock-based compensation expense | — | — | 18,865 | — | — | 18,865 |
| Unrealized gain on available-for-sale securities | — | — | — | 48 | — | 48 |
| Issuance of shares under employee stock purchase plan | 189,922 | — | 735 | — | — | 735 |
| Restricted common stock vesting | 112,159 | — | — | — | — | — |
| Issuance of common stock pursuant to the at-the market sales agreement, net of issuance costs of $1,107 | 2,955,082 | 1 | 23,893 | — | — | 23,894 |
| Net loss | — | — | — | — | (38,626) | (38,626) |
| Balance—December 31, 2025 | 65,543,723 | $7 | $714,090 | $(3,827) | $(477,214) | $233,056 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.